The Medical Devices Regulations 2002 © Crown Copyright 2002 Statutory Instruments printed from this website are printed under the superintendence and authority of the Controller of HMSO being the Queen's Printer of Acts of Parliament. The legislation contained on this web site is subject to Crown Copyright protection. It may be reproduced free of charge provided that it is reproduced accurately and that the source and copyright status of the material is made evident to users. It should be noted that the right to reproduce the text of Statutory Instruments does not extend to the Queen's Printer imprints which should be removed from any copies of the Statutory Instrument which are issued or made available to the public. This includes reproduction of the Statutory Instrument on the Internet and on intranet sites. The Royal Arms may be reproduced only where they are an integral part of the original document. The text of this Internet version of the Statutory Instrument which is published by the Queen's Printer of Acts of Parliament has been prepared to reflect the text as it was Made. A print version is also available and is published by The Stationery Office Limited as the The Medical Devices Regulations 2002, ISBN 0 11 042317 8. The print version may be purchased by clicking here. Braille copies of this Statutory Instrument can also be purchased at the same price as the print edition by contacting TSO Customer Services on 0870 600 5522 or e-mail:customer.services@tso.co.uk. Further information about the publication of legislation on this website can be found by referring to the Frequently Asked Questions. To ensure fast access over slow connections, large documents have been segmented into "chunks". Where you see a "continue" button at the bottom of the page of text, this indicates that there is another chunk of text available.
The Secretary of State, being a Minister designated for the purposes of section 2(2) of the European Communities Act 1972[1] in relation to measures relating to medical devices[2], in exercise of the powers conferred by the said section 2(2), in exercise, with the consent of the Treasury, of the powers conferred by section 56(1) and (2) of the Finance Act 1973[3], in exercise of the powers conferred by sections 11 and 27(2) of the Consumer Protection Act 1987[4], and in exercise of all other powers enabling him in that behalf, after consultation in accordance with section 11(5) of the Consumer Protection Act 1987 with organisations appearing to him to be representative of interests substantially affected by these Regulations, with such other persons considered by him appropriate and with the Health and Safety Commission, hereby makes the following Regulations: - Citation and commencement 1. These Regulations may be cited as the Medical Devices Regulations 2002 and shall come into force 13th June 2002. Interpretation 2. - (1) In these Regulations, unless the context otherwise requires -
(b) is intended to be totally or partially introduced into the human body (whether surgically or medically, including being introduced into a natural orifice) and which is intended to remain in the human body after completion of the surgical or medical procedure during which it is introduced,
even if it is intended to administer a medicinal product or incorporates as an integral part a substance which, if used separately, would be a medicinal product;
(b) in the context of any requirement relating to any other medical device, the European Economic Area;
(b) a monograph of the European Pharmacopoeia (in particular any monograph on surgical sutures and the interaction between medicinal products and materials used in medical devices containing medicinal products),
the reference number of which has been published in the Official Journal of the European Communities;
(b) in relation to any other medical device, that it is intended for use by a duly qualified medical practitioner or a professional user when conducting investigations of that device in an adequate human clinical environment;
(b) in relation to any other medical device, the use to which the device is intended according to the data supplied by the manufacturer on the labelling, the instructions for use and/or the promotional materials;
(b) is intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information -
(ii) concerning a congenital abnormality, (iii) to determine the safety and compatibility of donations, including blood and tissue donations, with potential recipients, or (iv) to monitor therapeutic measures,
and includes a specimen receptacle but not a product for general laboratory use, unless that product, in view of its characteristics, is specifically intended by its manufacturer to be used for in vitro diagnostic examination;
(b) any other person who assembles, packages, processes, fully refurbishes or labels one or more ready-made products or assigns to them their intended purpose as a device with a view to their being placed on the market under his own name, apart from a person who assembles or adapts devices already on the market to their intended purpose for an individual patient;
(ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, (iii) investigation, replacement or modification of the anatomy or of a physiological process, or (iv) control of conception; and
(b) does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, even if it is assisted in its function by such means,
and includes devices intended to administer a medicinal product or which incorporate as an integral part a substance which, if used separately, would be a medicinal product and which is liable to act upon the body with action ancillary to that of the device;
(b) in relation to any other medical device, the first making available of the device in the Community to a final user, including where a device is used in a professional context for the purposes of medical analysis without being marketed;
(b) is liable to act upon the human body with action ancillary to that of the device;
(b) the exposure or possession for supply of the device;
(2) In these Regulations, unless the context otherwise requires, a reference -
(b) in a regulation to a numbered or lettered paragraph is to the paragraph of that regulation bearing that number or letter; and (c) in a paragraph to a numbered or lettered sub-paragraph is to the sub-paragraph in that paragraph bearing that number or letter.
Scope of these Regulations
(b) human blood, human blood products, plasma or blood cells of human origin; (c) devices that incorporate, at the time of placing on the market, human blood, blood products, plasma or blood cells of human origin, except for stable derivatives devices; (d) transplants or tissues or cells of human origin or products incorporating or derived from tissues or cells of human origin; (e) transplants or tissues or cells of animal origin, unless a device is manufactured utilising animal tissue which is rendered non-viable or non-viable products derived from animal tissue; (f) cosmetic products governed by Council Directive 76/768/EEC[14], as amended[15]; or (g) products whose principal intended purpose is such that they fall under Council Directive 89/686/EEC on the approximation of the laws of the Member States relating to personal protective equipment[16], as amended[17].
Transitional provisions
(b) before 10th January 2009 in respect of a stable derivatives device put into service without a CE marking, if the device satisfies the requirements of the laws of that part of the United Kingdom in which it is placed on the market as in force on 10th January 2002.
(3) Part IV shall not be applied before 7th December 2003 in respect of a device placed on the market which is -
(b) a device for performance evaluation and the manufacturer or his authorised representative does not indicate, directly or indirectly, that it is a device which is subject to the provisions of these Regulations,
if the device satisfies the requirements of the laws of that part of the United Kingdom in which it is placed on the market as in force on 7th December 1998.
(b) a device for performance evaluation and the manufacturer or his authorised representative does not indicate, directly or indirectly, that it is a device which is subject to the provisions of these Regulations,
if the device satisfies the requirements of the laws of that part of the United Kingdom in which it is put into service as in force on 7th December 1998. Interpretation of Part II 5. - (1) In this Part, unless the context otherwise requires -
(b) intended for the sole use of a particular patient,
but does not include a mass-produced product which needs to be adapted to meet the specific requirements of the medical practitioner or professional user;
(2) In this Part, unless the context otherwise requires, a reference to a numbered article or Annex is to the article or Annex of Directive 93/42 bearing that number.
(b) in vitro diagnostic medical devices and accessories to such devices; and (c) devices that come within the scope of Directive 93/42 and another Directive ("the other Directive") issued by one or more of the institutions of the Community, and
(ii) the manufacturer chooses to follow the set of arrangements in the other Directive.
Classification of general medical devices
(b) in circumstances where that device has been placed on the market or put into service,
unless that device meets those essential requirements set out in Annex I which apply to it.
(b) the essential requirements specified in Sections 11.4 and 13 of Annex I with regard to instructions for use are complied with only if -
(ii) if the instructions are not in English, any packaging, label or promotional literature carries a clear statement in English stating the language in which the instructions are given.
(4) A relevant device shall be treated as complying with an essential requirement if it conforms as respects that requirement to a relevant national standard, unless there are reasonable grounds for suspecting that it does not comply with that requirement.
(b) in the case of a Class IIa, Class IIb and Class III device, which is accompanied by the statement required by Section 1 of Annex VIII,
shall be taken to comply with the relevant essential requirements unless there are reasonable grounds for suspecting that the device does not comply with those requirements.
(b) notice has been given under regulation 16(1); and (c) either -
(ii) notice has been given under regulation 16(5),
shall be taken to comply with the relevant essential requirements unless there are reasonable grounds for suspecting that the device does not comply with those requirements.
(8) A single-use combination product shall be taken to comply with the relevant essential requirements if the medical device which forms part of that product only complies with the requirements set out in Annex I of Directive 93/42 that relate to safety and performance, unless the medicinal product which forms part of that product is liable to act on the human body with action ancillary to that of the medical device, in which case the single-use combination product must comply with all the relevant essential requirements which apply to it.
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(2) Subject to regulations 12 and 14, no person shall supply a relevant device unless, where practical and appropriate, that device or its sterile pack bears a CE marking which -
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device,
if that supply is also a placing on the market or putting into service, or if that supply is of a device that has been placed on the market or put into service.
(b) the instructions for use for the device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for the device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for a relevant device; or (c) any sales packaging for a relevant device,
which is likely to mislead a third party with regard to the meaning or the graphics of the CE marking or which reduces the visibility or the legibility of the CE marking.
(b) the manufacturer chooses to follow the set of arrangements in Directive 93/42; (c) the marking of the device indicates that the device only satisfies the set of arrangements chosen by the manufacturer; and (d) the particulars of Directive 93/42, as published in the Official Journal of the European Communities, are given in the documents, notices or instructions accompanying the device.
Exemptions from regulations 8 and 10
(b) the chosen combination of medical devices is not compatible in view of their original intended use.
(4) Regulation 10 shall not apply to single-use combination products, unless the medicinal product which forms part of that product is liable to act on the human body with action ancillary to that of the medical device which forms part of that product.
(b) declares, in accordance with the declaration of conformity procedure set out in that Annex, that the device meets the provisions of Directive 93/42 which apply to it; and (c) ensures that the device meets the provisions of Directive 93/42 which apply to it.
(2) A relevant device falling within Class IIa may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annex VII, together with Annex IV, V or VI;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 93/42 which apply to it; and
(3) A relevant device falling within Class IIb may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annex III, together with Annex IV, V or VI;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 93/42 which apply to it; and
(4) A relevant device falling within Class III may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annex III, together with Annex IV or V;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 93/42 which apply to it; and
Procedures for systems and procedure packs, and for devices to be sterilised before use
(b) the person who places or has placed it on the market has drawn up a declaration that -
(ii) he has packaged the system or procedure pack and supplied relevant information to users incorporating relevant instructions from the manufacturers, and (iii) his production of the system or procedure pack is subjected to appropriate methods of internal control and inspection,
and that declaration is true at the time it is made and continues to be true.
(2) Subject to paragraph (3), no person shall supply -
(b) a relevant device (including a system or procedure pack) which is designed by its manufacturer to be sterilised before use,
(if that supply is also a placing on the market, or if that supply is of a device that has been placed on the market) unless the person who places, or who has placed, the device on the market satisfies the conditions set out in paragraph (4).
(b) if the device has been sterilised, make a written declaration that sterilisation has been carried out in accordance with the manufacturer's instructions.
(5) Where a conformity assessment procedure is carried out in respect of a relevant device (including a device which is a system or procedure pack) pursuant to this regulation -
(b) no person shall supply that device (if that supply is also a placing on the market, or if that supply is of a device that has been placed on the market) unless it is accompanied by the information referred to in Section 13 of Annex I, which shall include, where appropriate, the information supplied by the manufacturers of the devices which have been put together.
(6) The declarations referred to in paragraph (1)(b) and (4)(b) shall be kept available for the Secretary of State by the person responsible for placing the product on the market for a period of five years.
(b) has undertaken to keep available for the Secretary of State documentation allowing an understanding of the design, manufacture and performances of the device, including the expected performances, so as to allow assessment of conformity of the device with the requirements of Directive 93/42; and (c) takes all necessary measures to ensure that the manufacturing process ensures that each device manufactured according to that process conforms to the documentation referred to in the first paragraph of Section 3.1 of Annex VIII; and (d) keeps available for the Secretary of State, for a minimum period of five years, the information contained in the statement referred to in paragraph (a) and in the undertaking referred to in paragraph (b).
Procedures for general medical devices for clinical investigations
(b) an undertaking to keep available for the Secretary of State the documentation referred to in Section 3.2 of Annex VIII for a minimum period of five years.
(2) Paragraph (1) shall not apply in respect of an intended clinical investigation of a relevant device that bears a CE marking otherwise than in breach of regulation 13, unless the aim of the intended investigation is to determine whether the device may be used for a purpose other than that in respect of which it was CE marked in accordance with regulation 13.
(b) if the ethics committee opinion required under Section 2.2 of Annex VIII is not available, that the relevant device may be made available for the purposes of the intended investigation once a favourable opinion in respect of the investigational plan for the intended investigation has been delivered by the committee.
(6) A written notice pursuant to paragraph (5) may -
(b) at any time be withdrawn on grounds of public health or public policy by the Secretary of State.
(7) Where a written notice pursuant to paragraph (5) in respect of a relevant device has been withdrawn by the Secretary of State -
(b) no person shall supply that relevant device for the purposes of the investigation (if that supply is also a making available of the device),
unless the Secretary of State issues a further written notice pursuant to that paragraph stating that the relevant device may again be made available for the purposes of the investigation.
(b) authorise the assessment, including audit where necessary, of the effectiveness of the measures which he takes pursuant to this regulation; and (c) keep the information contained in the statement and the undertaking referred to in paragraph (1) for a minimum period of five years.
(9) The grounds of public health or public policy referred to in paragraph (4) or (6)(b) are met, amongst other reasons, if -
(b) the manufacturer or his authorised representative does not make available to the Secretary of State documentation which he has undertaken to keep available in accordance with paragraph (1)(b).
(10) No person shall conduct a clinical investigation of a relevant device -
(b) otherwise than in accordance with any conditions imposed by the Secretary of State pursuant to paragraph (6)(a),
and if a clinical investigation is conducted in respect of a relevant device, the manufacturer of that device or his authorised representative shall keep available for the Secretary of State the report referred to in Section 2.3.7 of Annex X.
(b) Section 2 of Annex VII shall fall upon the person who places on the market the device to which the documentation relates.
UK notified bodies and the conformity assessment procedures for general medical devices
(b) take account of any relevant information relating to the characteristics and performance of that device, including in particular the results of any relevant tests and verification relating to that device already carried out under the laws or administrative provisions in force before 1st January 1995 in any EEA State; and (c) lay down, by common accord with the manufacturer or his authorised representative, the time limits for completion of the assessment and verification operations referred to in Annex II to IV.
(2) Where a UK notified body takes a decision in accordance with Annex II or III, they shall specify the period of validity of the decision, which initially shall be for a period of not more than five years.
(b) supply the Secretary of State with a description of each category of device concerned.
(2) Paragraph (1) applies to -
(b) a person with a registered place of business in the United Kingdom who sterilises before use relevant devices designed by their manufacturer to be sterilised before use.
(3) Subject to paragraph (6), for the purpose of enabling the Secretary of State to exercise his functions under these Regulations, any person with a registered place of business in the United Kingdom who places a device mentioned in paragraph (2) on the market in the United Kingdom on behalf of a manufacturer who does not have a registered place of business in the Community or in a State which is a Party to an Association Agreement shall inform the Secretary of State of -
(b) the category of device; and (c) in the case of an authorised representative of the manufacturer, the fact that he is the manufacturer's authorised representative, and he shall furnish the Secretary of State with sufficient evidence that he is an authorised representative of the manufacturer.
(4) Subject to paragraph (6), for the purpose of enabling the Secretary of State to exercise his functions under these Regulations, any person with a registered place of business in the United Kingdom who places a system or procedure pack which is not CE marked on the market in the United Kingdom, or who sterilises systems or procedure packs before they are placed on the market, shall -
(b) supply the Secretary of State with descriptions of the devices which are included in any such system or procedure pack in a manner sufficient to identify them.
(5) Subject to paragraph (6), for the purpose of enabling the Secretary of State to exercise his functions under these Regulations, any person with a registered place of business in the United Kingdom who places a relevant device which is a Class IIb or III device on the market in the United Kingdom (including the authorised representative of a manufacturer of a Class IIb or III device who does not have a registered place of business in the Community or in a State which is a Party to an Association Agreement) shall, if the Secretary of State so requests, supply the Secretary of State with all data allowing for the identification of the device together with the label and the instructions for use for when the device is put into service within the United Kingdom.
(b) the manufacturer or his authorised representative has already registered with the competent authorities of that State.
Interpretation of Part III 20. - (1) In this Part, unless the context otherwise requires -
(b) intended to be used only for a particular patient; and
(2) In this Part, unless the context otherwise requires, a reference to a numbered article or Annex is to the article or Annex of Directive 90/385 bearing that number.
(b) the manufacturer chooses to follow the set of arrangements in the other Directive.
Essential requirements for active implantable medical devices
(b) in circumstances where that device has also been placed on the market or put into service,
unless that device meets those essential requirements set out in Annex 1 which apply to it.
(b) evaluation of side effects or undesirable effects for the purposes of determining whether or not a relevant device complies with any of the essential requirements,
shall be based in particular on clinical data, the adequacy of which is based on the collation of scientific literature or the results of clinical investigations referred to in paragraph 1 of Annex 7, and any determination as to whether or not a relevant device complies with any other essential requirements may be based on such data.
(b) the essential requirements specified in paragraph 13 of Annex 1, so far as they relate to instructions required for the operation of a device in paragraph 15 of Annex 1, are complied with only if -
(ii) if the instructions are not in English, any packaging, label or promotional literature carries a clear statement in English stating the language in which the instructions are given.
(4) A relevant device shall be treated as complying with an essential requirement if it conforms as respects that requirement to a relevant national Standard, unless there are reasonable grounds for suspecting that the device does not comply with that requirement.
(b) notice has been given under regulation 29(1); and (c) either -
(ii) notice has been given under regulation 29(4),
shall be taken to comply with the relevant essential requirements unless there are reasonable grounds for suspecting that the device does not comply with those requirements.
CE marking of active implantable medical devices
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(2) Subject to regulation 26, no person shall supply a relevant device unless that device or its sterile pack bears a CE marking which -
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device,
if that supply is also a placing on the market or putting into service, or if that supply is of a device that has been placed on the market or put into service.
(b) the instructions for use for the device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for the device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for a relevant device; or (c) where appropriate, any sales packaging for a relevant device,
which is likely to mislead a third party with regard to the meaning or the graphics of the CE marking or which reduces the visibility or the legibility of the CE marking.
(b) the manufacturer chooses to follow the set of arrangements in Directive 90/385; (c) the marking of the device indicates that the device only satisfies the set of arrangements chosen by the manufacturer; and (d) the particulars of Directive 90/385, as published in the Official Journal of the European Communities, are given in the documents, notices or instructions accompanying the device, and in a manner in which those particulars are accessible without it being necessary to destroy the packaging which keeps the device sterile.
Exemptions from regulations 22 and 24
(ii) Annex 3, together with Annex 4 or 5;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 90/385 that apply to it; and
Procedures for custom-made active implantable medical devices
(b) has undertaken to keep available for the Secretary of State the documentation referred to in Section 3.1 of Annex 6; (c) takes all necessary measures to ensure that the manufacturing process ensures that each device manufactured according to that process conforms to the documentation referred to in the first paragraph of Section 3.1 of Annex 6; and (d) keeps available for the Secretary of State the information contained in the statement referred to in paragraph (a) and in the undertaking referred to in paragraph (b).
Procedures for active implantable medical devices for clinical investigations
(b) an undertaking to keep available for the Secretary of State the documentation referred to in Section 3.1 and 3.2 of Annex 6.
(2) The ethics committee opinion that forms part of the information required under Section 2.2 of Annex 6 need not be provided to the Secretary of State at least 60 days prior to the intended investigation, but if it is not provided at least 60 days prior to the intended investigation, it must be provided to the Secretary of State by the manufacturer or his authorised representative as soon as it becomes available.
(b) if the ethics committee opinion required under Section 2.2 of Annex 6 is not available, that the relevant device may be made available for the purposes of the intended investigation once a favourable opinion in respect of the investigational plan for the intended investigation has been delivered by the committee.
(5) A written notice pursuant to paragraph (4) may -
(b) at any time be withdrawn on grounds of public health or public policy by the Secretary of State.
(6) Where a written notice pursuant to paragraph (4) in respect of a relevant device has been withdrawn by the Secretary of State -
(b) no person shall supply that relevant device for the purposes of the investigation (if that supply is also a making available of the device),
unless the Secretary of State issues a further written notice pursuant to that paragraph stating that the relevant device may again be made available for the purposes of the investigation.
(b) keep available for the Secretary of State the information contained in the statement and the undertaking referred to in paragraph (1); and (c) authorise the assessment, including audit where necessary, of the effectiveness of the measures which he takes pursuant to this regulation.
(8) The grounds of public health or public policy referred to in paragraphs (3) and (5)(b) are met, amongst other reasons, if -
(b) the manufacturer or his authorised representative does not make available to the Secretary of State documentation which he has undertaken to keep available in accordance with paragraph (1).
(9) No person shall conduct a clinical investigation of a relevant device -
(b) otherwise than in accordance with any conditions imposed by the Secretary of State pursuant to paragraph (5)(a),
and if a clinical investigation is conducted in respect of a relevant device, the manufacturer of that device or his authorised representative shall keep available for the Secretary of State the report referred to in Section 2.3.7 of Annex 7.
(b) lay down, by common accord with the manufacturer or his authorised representative, the time limits for completion of the assessment and verification operations referred to in Annex 2 or 3.
(2) Where a UK notified body takes a decision in accordance with Annex 2 or 3, they shall specify the period of validity of the decision, which initially shall be for a period of not more than five years. Interpretation of Part IV 32. - (1) In this Part, unless the context otherwise requires -
(b) an invasive sampling medical device; or (c) a medical device which is directly applied to the human body for the purpose of obtaining a specimen;
(2) In this Part, unless the context otherwise requires, a reference to a numbered article or Annex is to the article or Annex of Directive 98/79 bearing that number.
(b) devices that come within the scope of Directive 98/79 and another Directive ("the other Directive") issued by one or more of the institutions of the Community, and
(ii) the manufacturer chooses to follow the set of arrangements in the other Directive.
(2) The requirements of this Part in respect of devices for performance evaluation do not apply in respect of -
(b) devices that come within the scope of Directive 98/79 and another Directive ("the other Directive") issued by one or more of the institutions of the Community, and
(ii) the manufacturer chooses to follow the set of arrangements in the other Directive.
Essential requirements for in vitro diagnostic medical devices
(b) in circumstances where that device has been placed on the market or put into service, unless that device meets those essential requirements set out in Annex I which apply to it.
Determining compliance of in vitro diagnostic medical devices with relevant essential requirements
(b) the relevant device is a device for self-testing, in which case the instructions for use and the label must include a translation into the official language of any member State of the Community in which the device reaches a final user.
(3) A relevant device shall be presumed to comply with an essential requirement if it conforms as respects that requirement to a relevant national standard.
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(2) Subject to regulation 39, no person shall supply a relevant device unless, where practical and appropriate, that device bears a CE marking which -
(b) is in a visible, legible and indelible form; and (c) is accompanied by any relevant notified body or conformity assessment body identification number for that device,
if that supply is also a placing on the market or putting into service or if that supply is of a device that has been placed on the market or put into service.
(b) the instructions for use for that device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for that device,
and that CE marking is accompanied by any relevant notified body or conformity assessment body identification number for that device.
(b) the instructions for use for a relevant device; or (c) any sales packaging for a relevant device,
which is likely to mislead a third party with regard to the meaning or the graphics of the CE marking or which reduces the visibility or the legibility of the CE marking.
(b) the manufacturer chooses to follow the set of arrangements in Directive 98/79; (c) the marking of the device indicates that the device only satisfies the set of arrangements chosen by the manufacturer; and (d) the particulars of Directive 98/79, as published in the Official Journal of the European Communities, are given in the documents, notices or instructions accompanying the device.
In vitro diagnostic medical devices not ready for use
(b) supply a relevant device -
(ii) in circumstances where that device has been placed on the market or put into service,
which is not ready for use.
Exemptions from regulations 34, 36 and 38
(b) a visible sign clearly indicates that the device cannot be marketed or put into service until it complies with the requirements of Directive 98/79 or these Regulations.
(2) Regulations 34, 36 and 38 shall not apply where, following a duly justified request and in the interests of the protection of health, the Secretary of State has authorised, where appropriate for a specified period, the placing on the market or putting into service of a particular relevant device or relevant devices of a particular class or description without a CE marking, where appropriate subject to conditions (which are complied with), and has not withdrawn that authorisation.
(b) declares, in accordance with the declaration of conformity procedure set out in that Annex, that the device meets the provisions of Directive 98/79 which apply to it; and (c) ensures that the device meets the provisions of Directive 98/79 which apply to it.
(2) A relevant device which is a device for self-testing but which is not referred to in a list in Annex II may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annex IV, or (iii) Annex V and either Annex VI or Annex VII;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 98/79 which apply to it; and
(3) A relevant device referred to in List A in Annex II may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annexes V and VII;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 98/79 which apply to it; and
(4) A relevant device referred to in List B in Annex II may bear a CE marking only if its manufacturer or his authorised representative -
(ii) Annexes V and VI, or (iii) Annexes V and VII;
(b) declares, in accordance with a declaration of conformity procedure set out in those Annexes, that the device meets the provisions of Directive 98/79 which apply to it; and
Manufacturers etc. and conformity assessment procedures for in vitro diagnostic medical devices
(b) the technical documentation referred to in Annexes III to VIII relating to that device; and (c) the decisions, reports and certificates of notified bodies relating to that device,
for a period ending five years after the manufacture of the last product.
(b) take account of any relevant information relating to the characteristics and performance of that device, including in particular the results of any relevant tests and verification relating to that device already carried out before 7th June 2000; and (c) lay down, by common accord with the manufacturer or his authorised representative, the time limits for completion of the assessment and verification operations referred to in Annexes III to VII.
(2) Where a UK notified body takes a decision in accordance with Annex III, IV, or V, they shall specify the period of validity of the decision, which, initially, shall be a period of not more than 5 years.
(b) ensures that -
(ii) the relevant requirements of the Directive are complied with as respects that device; and
(c) undertakes to keep available, and keeps available, for the Secretary of State, for a minimum period of five years after the end of the performance evaluation, documentation allowing an understanding of the design, manufacture and performances of the device, including the expected performances, so as to allow assessment of conformity of the device with the requirements of these Regulations.
Registration of manufacturers etc. of in vitro diagnostic medical devices and devices for performance evaluation
(b) in the case of an authorised representative, sufficient evidence that he is the authorised representative of the manufacturer; (c) in relation to a new relevant device, a statement indicating that the device is a new relevant device, and for the purposes of this regulation a device is a "new relevant device" if -
(ii) use of the device involves analytical technology not continuously used in connection with a given analyte or other parameter on the Community market during the previous three years;
(d) in relation to a new relevant device, if requested by the Secretary of State (such a request only being permissible within two years from the date on which the Secretary of State was notified that the device was a new relevant device, and on justified grounds), a report relating to the experience gained with the device subsequent to its being placed on the market;
(ii) if requested by the Secretary of State, the labelling and the instructions for use for when the device is placed on the market or put into service within the United Kingdom; and
(h) in relation to devices for performance evaluation which relate either to devices referred to in a list in Annex II or to devices for self- testing, all data allowing for identification of such devices, the analytical and, where appropriate, diagnostic parameters as referred to in Section 3 of Part A of Annex I,
and shall notify him of any significant change to that information including discontinuation of the placing on the market of the device.
(b) a person with a registered place of business in the United Kingdom who places a relevant device on the market in the United Kingdom, or who makes available a device for performance evaluation, on behalf of a manufacturer who does not have a registered place of business in the Community or in a State which is a Party to an Association Agreement as his authorised representative.
(3) Registration under this regulation is not required if -
(b) the manufacturer or his authorised representative has already registered with the competent authorities of that other State.
Designation etc. of UK notified bodies 45. - (1) The Secretary of State may designate for the purposes of article 11 of Directive 90/385, article 16 of Directive 93/42 or article 15 of Directive 98/79 any corporate or other body as a body which is to carry out any of the tasks of a notified body, and, if he so designates a body (referred to in these Regulations as a "UK notified body"), he shall designate the tasks which it is to carry out. (2) A body may be designated under paragraph (1) as a body which is to carry out tasks of a notified body only if -
(b) in so far as it is to be designated as a body which is to carry out tasks included in Directive 93/42, it is a body in respect of which the criteria for the designation of notified bodies set out in Annex XI of that Directive are met; (c) in so far as it is to be designated as a body which is to carry out tasks included in Directive 98/79, it is a body in respect of which the criteria for the designation of notified bodies set out in Annex IX of that Directive are met; and (d) in so far as it needs to be able to fulfil the functions of an importing Party arising out of the Mutual Recognition Agreements, it is able to do so.
(3) The Secretary of State may refuse to designate a body under paragraph (1) if it fails to pay any fee payable under Part VI in connection with an application for designation.
(b) he considers that it is no longer a body in respect of which the applicable criteria for designation set out in Annex 8 of Directive 90/385, Annex XI of Directive 93/42 or Annex IX of Directive 98/79 are met; or (c) he considers that the body is not capable of fulfilling the functions of an importing Party arising out of the Mutual Recognition Agreements which it needs to be able to fulfil,
and the Secretary of State may also withdraw any designation of a body under paragraph (1) if it fails to pay any fee payable under Part VI.
(b) restricting or withdrawing a designation under paragraph (5),
otherwise than at the notified body's request, the Secretary of State shall give to the notified body an opportunity to make representations to him in writing and shall take into account any such representations as are made.
(b) any premises occupied, or plant or equipment used, by a manufacturer where the body is undertaking any task in relation to that manufacturer,
and may take into account for the purposes of his decision the results of any such inspection and any refusal to afford him such facilities or assistance as he may reasonably require in order to carry out any such inspection.
(b) for the purposes of deciding whether or not the body is capable of fulfilling the functions of an importing Party arising out of the Mutual Recognition Agreements which it needs to be able to fulfil,
and the body shall supply to him any and all relevant information or documents so requested.
(b) on request, all certificates issued or refused,
and shall also make available to them, on request, any or all additional relevant information.
(b) a certificate issued by it should not have been issued,
it may (having regard in particular to the principle of proportionality and the ability of the manufacturer to take appropriate corrective measures) suspend or withdraw the certificate issued in respect of that device or place restrictions on it, and in such cases, or in cases where the notified body is aware of circumstances in which the Secretary of State may need to take action pursuant to regulation 61, the notified body shall inform the Secretary of State thereof.
(b) he considers that the body is not capable of fulfilling the functions of an EC CAB arising out of the Mutual Recognition Agreements which it needs to be able to fulfil,
and the Secretary of State may also withdraw any designation of a body under paragraph (1) if it fails to pay any fee payable under Part VI.
(b) restricting or withdrawing a designation under paragraph (5),
otherwise than at the EC CAB's request, the Secretary of State shall give to the EC CAB an opportunity to make representations to him in writing and shall take into account any such representations as are made.
(b) any premises occupied, or plant or equipment used, by a manufacturer where the body is undertaking any task in relation to that manufacturer,
and may take into account for the purposes of his decision the results of any such inspection and any refusal to afford him such facilities or assistance as he may reasonably require in order to carry out any such inspection.
(b) in the case of an EC CAB, performing the functions of an EC CAB arising out of the Mutual Recognition Agreements in respect of a conformity assessment procedure for a medical device.
(2) Except as provided for by paragraph (3), the fee charged in respect of anything done shall not exceed an amount which reasonably represents the cost incurred, or to be incurred, in doing it.
(b) the commercial rate normally charged in respect of profit for that work or similar work.
(4) The UK notified body or EC CAB may require payment of the fee, or a reasonable estimate of the fee, in advance of carrying out the work in respect of which the fee is payable and as a condition of doing that work.
(b) supply a medical device (if that supply is also a placing on the market, or if that supply is of a device which has been placed on the market) which has affixed to it a notified body or conformity assessment body number if that body -
(ii) has had its designation as a notified body or conformity assessment body withdrawn.
(2) No person shall provide information comprising a notified body or conformity assessment body number on a medical device, the instructions for use for a medical device, or the sales packaging for a medical device if that device -
(b) the notified body or conformity assessment body -
(ii) has had its designation as a notified body or conformity assessment body withdrawn.
(3) Where the sectoral annex on medical devices in a Mutual Recognition Agreement under which a conformity assessment body was designated states that the annex does not apply to devices of a particular class or description, no person may supply a medical device of that class or description bearing the number of that conformity assessment body (if that supply is also a placing on the market or putting into service or is of a device that has been placed on the market or put into service) unless -
(b) the device bears the notified body number of that notified body.
(4) For the purposes of this regulation, a notified body shall be taken to have carried out an assessment in respect of a device if it has endorsed a report prepared by a third country conformity assessment body in respect of that device.
(b) supply a product (if that supply is also a placing on the market, or if that supply is of a product which has been placed on the market) which has affixed to it the CE marking for a medical device if that product is not a medical device.
(2) No person shall provide information comprising a CE marking for a medical device on a product, the instructions for use for a product, or the sales packaging for a product if the product is not a medical device. Interpretation of Part VI 52. - (1) In this Part, unless the context otherwise requires -
(2) For the purposes of this Part, medical devices are classified as being implantable or long term invasive medical devices in accordance with the definitions set out in Section 1 of Annex IX of Directive 93/42, and in the event of a dispute over the classification of a device, the Secretary of State shall determine the classification of the device in accordance with the definitions set out in Section 1 of Annex IX of Directive 93/42.
(b) shall accompany that information when it is supplied.
Fees payable in connection with the designation etc. of UK notified bodies
(b) in all other cases, a fee of £2,600.
(2) A corporate or other body that applies to the Secretary of State for a variation under regulation 45(4) of the tasks that the body may carry out shall, in connection with that application for a variation, pay to the Secretary of State a fee of £1,300.
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses;
(b) in respect of any other inspection pursuant to regulation 45(7)(a), a fee of £2,600, plus -
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses; and
(c) in respect of an inspection pursuant to regulation 45(7)(b), a fee of £2,600, plus -
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses.
(4) A fee under this regulation -
(ii) shall accompany the application when it is made;
(b) in connection with an inspection pursuant to regulation 45(7), shall be payable within one month of receipt by the body of a written notice from the Secretary of State requiring payment of the fee.
Fees payable in connection with the designation etc. of EC conformity assessment bodies
(b) in all other cases, a fee of £2,600.
(2) A corporate or other body that applies to the Secretary of State for a variation under regulation 48(4) of the tasks that the body may carry out shall, in connection with that application for a variation, pay to the Secretary of State a fee of £1,300.
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses;
(b) in respect of any other inspection pursuant to regulation 48(7)(a), a fee of £2,600, plus -
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses; and
(c) in respect of an inspection pursuant to regulation 48(7)(b), a fee of £2,600, plus -
(ii) the actual costs of travel, accommodation and subsistence, and (iii) out of pocket expenses.
(4) A fee under this regulation -
(ii) shall accompany the application when it is made;
(b) in connection with an inspection pursuant to regulation 48(7), shall be payable within one month of receipt by the body of a written notice from the Secretary of State requiring payment of the fee.
Fees payable in relation to clinical investigation notices
(ii) a fee, if the device is a Group B device, of £2,100; or
(b) in all other cases -
(ii) a fee, if the device is a Group B device, of £3,000.
(2) Except where paragraph (3) applies, no fee shall be payable in respect of a notice of the supply of a device for the purposes of a clinical investigation under regulation 16(1) or 29(1) where the manufacturer or his authorised representative has previously given such notice in relation to that device.
(b) a change to the number of patients or devices forming the basis of the proposed trial; (c) a change or extension in the indications for use of the device or to the purpose or objectives of the trial; (d) a change in any of the materials used in the device that come into direct contact with the human body if the new materials are not known to be biocompatible; or (e) a change in the design of the device involving a novel feature not previously tested, being a change that has a direct effect on a vital physiological function.
(4) A fee under this regulation -
(b) shall accompany that notice when it is given.
Unpaid fees
(b) refund the whole or part of any fee paid pursuant to this Part.
(2) Without prejudice to the generality of paragraph (1), where -
(b) an application for designation as -
(ii) an EC CAB under regulation 48(1),
(other than one submitted only to address the grounds of rejection of a previous application) is withdrawn within the period of 21 days beginning with the date of its receipt by the Secretary of State,
Interpretation of Part VII 59. In this Part, unless the context otherwise requires -
Designation etc. of authorised representatives
(b) supply that device in circumstances where it has been placed on the market,
unless the manufacturer of the device has designated an authorised representative to perform that obligation, but once the manufacturer has designated an authorised representative to perform that obligation, that obligation shall be performed by the authorised representative (although in all other cases it shall be performed by the manufacturer).
(b) the person responsible for registering in respect of that device with -
(ii) the competent authorities of another Member State or (where appropriate) a State which is a Party to an Association Agreement.
(3) Where a manufacturer of a registrable device, or of a relevant device that is not registrable, has designated an authorised representative as the person responsible for marketing the device within the Community, that authorised representative -
(b) in relation to any supply of the device to a person within the United Kingdom after it has been placed on the market, may be proceeded against as a person supplying the device after it has been placed on the market, unless that supply is due to an act of another person established in the Community or in a State which is a Party to an Association Agreement.
(4) If a person claims or purports to act as an authorised representative of a manufacturer of a device, the Secretary of State may, for the purposes of enabling the Secretary of State to exercise his functions under these Regulations, require that person to furnish the Secretary of State with sufficient evidence that he is an authorised representative of the manufacturer.
(b) any application made by it under section 16 of the 1987 Act for an order for forfeiture of any such device; and (c) any other thing done by it in respect of such a device for the purposes of, or in connection with the operation of, sections 14 to 17 of the 1987 Act.
(6) In respect of an offence committed under section 12 of the 1987 Act relating to a contravention of these Regulations -
(b) a magistrates' court in Northern Ireland may hear and determine any complaint made within 12 months from the time when the offence was committed; and (c) in Scotland, summary proceedings for the offence may be commenced at any time within 12 months from the time when the offence was committed.
(7) The powers conferred by section 13 of the 1987 Act to serve prohibition notices and notices to warn are exercisable in relation to non - conforming devices as they are exercisable in relation to relevant goods which the Secretary of State considers are unsafe (as well as being exercisable in relation to goods considered unsafe by the Secretary of State), and in relation to non-conforming devices, Schedule 2 to the 1987 Act shall have effect as if references to goods being unsafe or safe were references to relevant devices being or not being non-conforming devices.
(ii) to which a CE marking has or should have been applied following a conformity assessment procedure set out in the Medical Devices Directives, and -
(aa) the manufacturer or his authorised representative has failed to comply with his obligations under that procedure, or
Compliance notices
(b) stating that the enforcement authority suspects the device is a device in respect of which there is failure to comply with these Regulations and the reasons for that suspicion; (c) specifying the relevant provision of these Regulations and, where applicable, any relevant provision of the Medical Devices Directives; (d) requiring the person on whom the notice is served -
(ii) to provide evidence within that period to the satisfaction of the enforcement authority that all the provisions of these Regulations have been complied with in so far as they relate to that device; and
(e) warning the person on whom the notice is served that unless the requirements of sub - paragraph (d) are met, further action may be taken under these Regulations or the 1987 Act in respect of that device or any device of the same type supplied by that person.
(2) Where an enforcement authority serves a notice referred to in paragraph (1), section 14, 16 or 17 of the 1987 Act shall not be applied as respects any device to which the notice relates until the period referred to in paragraph (1)(d) has expired and unless, in relation to the alleged failure to comply with these Regulations, at the expiry of that period the person on whom the notice was served has failed to comply with its requirements.
(b) medical devices, accessories to such devices or devices for performance evaluation of a particular class or description,
in order to protect the health or safety of any individual or of individuals of any class or description, they may serve on any person a notice ("a restriction notice") including such directions restricting the availability of that device or those devices as appear to them to be necessary in order to protect the health or safety of that individual or individuals of that class or description.
(b) under section 16 or 17 of the 1987 Act (which relate to forfeiture of goods), the court or the sheriff may make an order setting aside the restriction notice,
if the court or the sheriff is satisfied that the restriction notice should not have been served or should be withdrawn.
(b) of the legal remedies available to that person and of any time limits which apply to their exercise; and (c) if the applicant was not entitled under the 1987 Act to make representations in respect of the decision, that the decision maker will, on request, review the decision and in the course of so doing will give him or his authorised representative an opportunity to make representations in respect of the decision.
(2) Except in cases where urgent action is justified (in particular by public health requirements), if a UK notified body, the Secretary of State or any other enforcement authority is considering making a decision referred to in paragraph (1), they or he shall give the manufacturer or his authorised representative an opportunity to make representations to them or him before the decision is taken.
(b) the Medical Devices Regulations 1994[24]; (c) the Active Implantable Medical Devices (Amendment and Transitional Provisions) Regulations 1995[25]; (d) the Medical Devices Fees Regulations 1995[26]; (e) the Medical Devices Fees (Amendment) Regulations 1997[27]; (f) the In Vitro Diagnostic Medical Devices Regulations 2000[28]; and (g) regulations 6 and 13 of the Medicines (Codification Amendments Etc.) Regulations 2002[29].
1. The Protocol to the Europe Agreement establishing an Association between the European Communities and their Member States, of the one part, and the Republic of Hungary, of the other part, on Conformity Assessment and Acceptance of Industrial Products[30]. 1. The agreement on mutual recognition in relation to conformity assessment certificates and markings between the European Community and Australia, initialled on 19th July 1996[31]. 2. The agreement on mutual recognition in relation to conformity assessment between the European Union and New Zealand, initialled on 19th July 1996[32]. 3. The agreement on mutual recognition between the European Community and Canada, signed in London on 14th May 1998[33]. 4. The agreement on mutual recognition between the European Community and the United States of America, signed in London on 18th May 1998[34]. (This note is not part of the Regulations) These Regulations contain the legislative measures necessary for the implementation of three European Community Directives: Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, as amended; Council Directive 93/42/EEC concerning medical devices, as amended; and Directive 98/79/EC of the European Parliament and of the Council on in vitro diagnostic medical devices ("the Medical Devices Directives"). They also contain the legislative measures necessary for the implementation, in relation to medical devices, of the agreements on mutual recognition between the European Community and Australia, New Zealand, Canada and the United States of America - and of the Association Agreement between the European Communities, and their Member States, and Hungary. Part I contains introductory provisions. These include an interpretation provision (regulation 2), and provisions both limiting the scope of the application of the Regulations so that they only apply to products covered by the Medical Devices Directives (regulation 3) and delaying the application of provisions of the Regulations in relation to specific categories of medical devices, to take account of the transitional arrangements in the Medical Devices Directives (regulation 4). Part II deals with the marketing of medical devices generally, but not with active implantable medical devices or in vitro diagnostic medical devices. Medical devices covered by this Part must generally meet the essential requirements set out in Annex I to Directive 93/42/EEC (regulations 8 and 9), and must be CE-marked according to the conformity assessment procedures set out in that Directive (regulations 10 and 13). There are exemptions for certain products (regulation 12), and special arrangements for products covered by more than one European Community Directive (regulation 11). There are also specific arrangements for systems and procedure packs, custom-made devices and devices intended for clinical investigations (regulations 14 to 16). Arising out of the conformity assessment procedures, there are specific obligations placed on manufacturers of devices or their authorised representatives (regulation 17), and on the notified bodies involved in carrying out assessments in respect of devices (regulation 18). Manufacturers of certain medical devices, or their authorised representatives, must register with the Secretary of State (regulation 19). Part III deals with active implantable medical devices. Again, these can only be marketed if they meet specified essential requirements, set out in Directive 90/385/EEC (regulations 22 and 23), and are assessed under conformity assessment procedures (regulations 24 and 27). There are special arrangements for devices that come under more than one European Community Directive (regulation 25), and some exemptions from the scheme (regulation 26). Again, there are different procedures for custom-made devices and devices for clinical investigation (regulations 28 and 29). Specific obligations are imposed on manufacturers or their authorised representatives (regulation 30), and on notified bodies carrying out assessments in respect of the devices (regulation 31). Part IV deals with in vitro diagnostic medical devices. These also must conform to the essential requirements set out in Directive 98/79/EC (regulations 33 and 34), and must be CE-marked according to one of the conformity assessment procedures set out in the Directive (regulations 36 and 40). There are again exemptions (regulation 39), and special arrangements for products caught by more than one European Community Directive (regulation 37). There are also special arrangements for devices for performance evaluation (regulation 43). Manufacturers or their authorised representatives have specific obligations relating to the conformity assessment procedures (regulation 41), and generally have to register (regulation 44). Notified bodies also have specific obligations relating to the conformity assessment procedures (regulation 42). Part V contains general provisions relating to the designation of notified bodies within the United Kingdom (regulation 45). Companies may apply to any European Community notified body or third country conformity assessment body (the equivalent body under a Mutual Recognition Agreement) to carry out tasks under a conformity assessment procedure, if the task is within the framework of tasks that the body is designated to carry out (regulation 46). There are also provisions for designating conformity assessment bodies to carry out conformity assessment work for other Parties to Mutual Recognition Agreements (regulation 48). This Part also contains prohibitions on marking products with CE marks or with notified body or conformity assessment body numbers if they are not entitled to bear those markings (regulations 50 and 51). Part VI sets out the fees charged by the Secretary of State in relation to work done pursuant to the Regulations. These include charges in connection with the registration of devices and changes to registration details (regulation 53), charges to UK notified bodies and EC Conformity Assessment Bodies (regulations 54 and 55), and fees payable in connection with clinical investigation notices (regulation 56). There are also arrangements for unpaid fees, waivers, reductions and refunds (regulations 57 and 58). Part VII includes general matters, including the provisions relating to designation of authorised representatives and enforcement (regulations 60 to 64), and requirements to keep a centralised system of records (regulation 65). This Part also contains revocations of provisions that are superseded as a result of the coming into force of these Regulations (regulation 66). A Regulatory Impact Appraisal and a Transposition Note in relation to the implementation of Directives 2000/70/EC and 2001/104/EC (the two most recent Directives amending Council Directive 93/42/EEC), have been placed in the libraries of both Houses of Parliament, and copies can be obtained from the Medical Devices Agency, Hannibal House, Elephant and Castle, London SE1 6TQ. Notes: [1] 1972 c. 68.back [2] The Secretary of State was designated in relation to measures relating to active implantable medical devices in S.I. 1991/2289, and in relation to measures relating to medical devices other than active implantable medical devices in S.I. 1993/2661.back [5] OJ No. L. 189, 20.7.1990, p.17.back [6] Council Directive 90/385/EEC has been amended by Council Directive 93/42/EEC (OJ No. L. 169, 12.7.1993, p.1) and Council Directive 93/68/EEC (OJ No. L 220, 30.8.1993, p.1).back [7] OJ No. L 169, 12.7.1993, p.1.back [8] Council Directive 93/42/EEC has been amended by Directive 98/79/EC (OJ No. L 331, 7.12.1998, p.1), Directive 2000/70/EC (OJ No. L 313, 13.12.2000, p.22) and Directive 2001/104/EC (OJ No. L 6, 10.1.2002, p.50).back [9] OJ No. L 331, 7.12.1998, p.1.back [10] OJ No. L 311, 28.11.2001, p.67.back [11] OJ No. L 1, 3.1.1994, p.3.back [12] OJ No. L 1, 3.1.1994, p.572.back [13] OJ No. L 204, 21.7.1998, p.37; amended by Directive 98/48/EC (OJ No. L 217, 5.8.1998, p.18).back [14] OJ No. L 262, 27.9.1976, p.169.back [15] Council Directive 76/768/EEC was amended for the twenty-sixth time by Commission Directive 2000/41/EC (OJ No. L 145, 20.6.2000, p.25).back [16] OJ No. L 399, 30.12.1989, p.18.back [17] Council Directive 89/686/EEC has been amended by Council Directive 93/68/EEC (OJ No. L 220, 30.8.1993, p.1), Council Directive 93/95/EEC (OJ No. L 276, 9.11.1993, p.11) and Council Directive 96/58/EC (OJ No. L 236, 18.9.1996, p.44).back [19] Council of Europe (ETS No. 164), Orviedo, 4.4.1997.back [20] See section s 11(1) and 45(1) of that Act.back [21] See section 45(1) of that Act.back [22] See section 11(7) of that Act.back [30] OJ No. L 135, 17.5.2001, p.35.back [31] OJ No. L 229, 17.8.1998, p.3.back [32] OJ No. L 229, 17.8.1998, p.62.back [33] OJ No. L 280, 16.10.1998, p.3.back [34] OJ No. L 31, 4.2.1999, p.3.back
ISBN 0 11 042317 8
|
|
| ||
| We welcome your comments on this site | © Crown copyright 2002 | Prepared 6 June 2002 |